Status:
TERMINATED
The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure
Lead Sponsor:
Nara Medical University
Conditions:
Heart Failure
Renal Failure
Eligibility:
All Genders
20-80 years
Phase:
PHASE4
Brief Summary
Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angi...
Eligibility Criteria
Inclusion
- Heart failure of any etiology, diagnosed according to Framingham criteria
- Estimated GFR \</= 60 ml/min/1.73 m2)
Exclusion
- Severe heart failure required percutaneous cardiopulmonary bypass support (PCPS)
- End-stage renal failure on maintenance dialysis
- Severe hepatic dysfunction
- Severe anemia
- Allergic history of carperitide
- Pregnant women
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2013
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00613964
Start Date
May 1 2009
End Date
May 1 2013
Last Update
July 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Department of Internal Medicine, Nara Medical University
Nara, Japan, 634-8522